Fig. 3
From: A tardive dyskinesia drug target VMAT-2 participates in neuronal process elongation
Treatment with reserpine leads to decreased process elongation. (A, B) Following the induction of differentiation, N1E-115 cells were treated with reserpine or its vehicle and cultured for 3 days. The morphology of the cells at day 0 is also depicted in the diagram. Cells with processes were counted and graphically represented (** p < 0.01; n = 10 fields). (C, D) The lysates of cells treated with reserpine or its vehicle were used for immunoblotting with antibodies against GAP43, Tau, and control actin. The expression levels of GAP43 and Tau were normalized to those of actin and graphically represented (** p < 0.01; n = 3 blots).
